An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.
- DOI
- 10.1093/cid/ciaf646
- Published
- 2026-02-01
- Container
- Clin Infect Dis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/cid/ciaf646,
title = {An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.},
author = {Papanicolaou GA and Dadwal SS and Ariza-Heredia EJ and Chiusolo P and Morris MI and Tholouli E and Haber B and Broyde N and Gilbert CL and Badshah C.},
year = {2026},
journal = {Clin Infect Dis},
doi = {10.1093/cid/ciaf646},
url = {https://doi.org/10.1093/cid/ciaf646}
}RIS
TY - JOUR TI - An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant. AU - Papanicolaou GA AU - Dadwal SS AU - Ariza-Heredia EJ AU - Chiusolo P AU - Morris MI AU - Tholouli E AU - Haber B AU - Broyde N AU - Gilbert CL AU - Badshah C. PY - 2026 JO - Clin Infect Dis DO - 10.1093/cid/ciaf646 UR - https://doi.org/10.1093/cid/ciaf646 ER -
APA
GA, P., SS, D., EJ, A., P, C., MI, M., E, T., B, H., N, B., CL, G., & C., B. (2026). An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.. Clin Infect Dis. https://doi.org/10.1093/cid/ciaf646
Source records
- europe-pmc · retrieved 2026-09-27T07:45:10.208Z